Evidence map›Paper›PMID 36555169›Full record

ArticleInternational journal of molecular sciences2022

Semi-Quantitative [

Olivier Espitia, Jérémy Schanus, Christian Agard, Françoise Kraeber-Bodéré, Alexis F Guédon, Antoine Bénichou, Jean-Michel Serfaty, Sandrine Coudol, Matilde Karakachoff, Bastien Jamet

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Emerging PET radiotracers for vascular imaging.Rheumatology (Oxford, England) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Olivier EspitiaDepartment of Internal and Vascular Medicine, CHU Nantes, Nantes Université, F-44000 Nantes, France.ORCID 0000-0003-0821-9990
Jérémy SchanusDepartment of Internal and Vascular Medicine, CHU Nantes, Nantes Université, F-44000 Nantes, France.
Christian AgardDepartment of Internal and Vascular Medicine, CHU Nantes, Nantes Université, F-44000 Nantes, France.ORCID 0000-0002-1156-0607
Françoise Kraeber-BodéréDepartment of Nuclear Medicine, CHU Nantes, Nantes Université, CNRS, INSERM, CRCINA, F-44000 Nantes, France.
Alexis F GuédonDepartment of Internal and Vascular Medicine, CHU Nantes, Nantes Université, F-44000 Nantes, France.
Antoine BénichouDepartment of Internal and Vascular Medicine, CHU Nantes, Nantes Université, F-44000 Nantes, France.
Jean-Michel SerfatyDepartment of Cardiovascular Imaging, CHU Nantes, Nantes Université, F-44000 Nantes, France.ORCID 0000-0001-8801-1414
Sandrine CoudolPôle Hospitalo-Universitaire 11, Santé Publique, Clinique des Données, CHU Nantes, Nantes Université, INSERM, CIC 1413, F-44000 Nantes, France.
Matilde KarakachoffPôle Hospitalo-Universitaire 11, Santé Publique, Clinique des Données, CHU Nantes, Nantes Université, INSERM, CIC 1413, F-44000 Nantes, France.
Bastien JametDepartment of Nuclear Medicine, CHU Nantes, Nantes Université, CNRS, INSERM, CRCINA, F-44000 Nantes, France.ORCID 0000-0002-2145-9182
Centre Hospitalier Universitaire de Nantes · FRCentre National de la Recherche Scientifique · FRInserm · FRNantes Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[18F]fluorodeoxyglucose-positron emission tomography/computed tomography ([18F]FDG-PET/CT) is used to diagnose large vessel vasculitis in giant cell arteritis (GCA). We aimed to define a semi-quantitative threshold for identifying GCA aortitis from aortic atheroma or the control. Contrast enhanced computed tomography (CECT) was used as the reference imaging for aortic evaluation and to define aortitis, aortic atheroma and control aortas. [18F]FDG-PET/CT was performed on 35 GCA patients and in two different control groups (aortic atheroma (n = 70) and normal control (n = 35)). Aortic semi-quantitative features were compared between the three groups. GCA patients without aortitis on CECT were excluded. Of the GCA patients, 19 (54.3%) were not on glucocorticoids (GC) prior to [18F]FDG-PET/CT. The SUVmax, TBRblood and TBRliver aortic values were significantly higher in the GCA aortitis group than in the aortic atheroma and control groups (p < 0.001). Receiver operating characteristic curve analyses brought to light quantitative cut-off values allowing GCA aortitis diagnosis with optimal sensitivity and specificity versus control or aortic atheroma patients for each PET-based feature analyzed. Considering the overall aorta, a SUVmax threshold of 3.25 and a TBRblood threshold of 1.75 had a specificity of 83% and 75%, respectively, a sensitivity of 81% and 81%, respectively, and the area under the ROC curve (AUC) was 0.86 and 0.83, respectively, for aortitis detection compared to control groups in GCA cases with GC. A SUVmax threshold of 3.45 and a TBRblood threshold of 1.97 had a specificity of 90% and 93%, respectively, a sensitivity of 89% and 89%, respectively, with an AUC of 0.89 and 0.96, respectively, for aortitis detection compared to the control in GC-free GCA cases. Discriminative thresholds of SUVmax and TBRblood for the diagnosis of GCA aortitis were established using CECT as the reference imaging.

Indexed as

AortitisGiant Cell ArteritisPlaque, AtheroscleroticFluorodeoxyglucose F18HumansPositron Emission Tomography Computed TomographyRadiopharmaceuticalsRetrospective StudiesROC CurveFluorodeoxyglucose F18Radiopharmaceuticals[18F]FDG-PET/CTaortic atheromaaortitisdiagnostic semi-quantitative thresholdsgiant cell arteritislarge vessel vasculitis

Identifiers

PMID36555169
PMCPMC9779846
OpenAlexW4311853062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.